Rapid Development of an Efficacious Swine Vaccine for Novel H1N1

Veen, Ryan Vander; Kamrud, Kurt I.; Mogler, Mark; Loynachan, Alan T.; McVicker, Jerry; Berglund, Peter; Owens, Gary; Timberlake, Sarah; Lewis, Whitney; Smith, Jonathan; Harris, D. H.

doi:10.1371/currents.rrn1123

Cited by 23 publications

(22 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In all cases antibodies were induced by vaccination, and pigs could at least be partially protected from infection with the homologous virus. [108][109][110][111][112] Heterosubtypic immunity could be induced when pigs were vaccinated with the VEE-NP construct, 112 however VEE-based vaccines performed poorly in the presence of maternal antibodies. 108 A VEE-based candidate vaccine against cytomegalovirus (CMV) has been tested in clinical trials, was shown to be immunogenic, well tolerated and safe in humans.…”

Section: Alphavirus Vectorsmentioning

confidence: 99%

Viral vector-based influenza vaccines

Vries

Rimmelzwaan

2016

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

Antigenic drift of seasonal influenza viruses and the occasional introduction of influenza viruses of novel subtypes into the human population complicate the timely production of effective vaccines that antigenically match the virus strains that cause epidemic or pandemic outbreaks. The development of game-changing vaccines that induce broadly protective immunity against a wide variety of influenza viruses is an unmet need, in which recombinant viral vectors may provide. Use of viral vectors allows the delivery of any influenza virus antigen, or derivative thereof, to the immune system, resulting in the optimal induction of virus-specific B- and T-cell responses against this antigen of choice. This systematic review discusses results obtained with vectored influenza virus vaccines and advantages and disadvantages of the currently available viral vectors.

show abstract

Section: Alphavirus Vectorsmentioning

confidence: 99%

Viral vector-based influenza vaccines

Vries

Rimmelzwaan

2016

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

show abstract

“…Pigs were vaccinated and challenged with the homologous pandemic virus. Vaccinated pigs showed a significantly higher specific antibody response, reduced lung lesions and viral shedding, and higher average daily weight gain compared to non-vaccinated control infected animals, indicating that the VEEV replicon vaccine is efficacious for swine against the pandemic H1N1 virus (Vander Veen et al, 2009). This VEEV replicon vaccine has obtained a conditional license in the USA.…”

Section: Alphavirus-based Siv Vaccinesmentioning

confidence: 99%

Swine influenza vaccines: current status and future perspectives

Richt

2010

Anim. Health. Res. Rev.

View full text Add to dashboard Cite

Swine influenza is an important contagious disease in pigs caused by influenza A viruses. Although only three subtypes of influenza A viruses, H1N1, H1N2 and H3N2, predominantly infect pigs worldwide, it is still a big challenge for vaccine manufacturers to produce efficacious vaccines for the prevention and control of swine influenza. Swine influenza viruses not only cause significant economic losses for the swine industry, but are also important zoonotic pathogens. Vaccination is still one of the most important and effective strategies to prevent and control influenza for both the animal and human population. In this review, we will discuss the current status of swine influenza worldwide as well as current and future options to control this economically important swine disease.

show abstract

“…These efforts have been aimed at retargeting the host immune response and stimulating the production of broadly reactive antibodies against the HA and/or other viral proteins. Plasmid DNA (37)(38)(39)(40), recombinant adenoviruses (41-44), alphavirus replicon particles (45)(46)(47)(48), VLPs (49)(50)(51)(52)(53)(54)(55), and other methods have been used for influenza virus gene/protein delivery, alone or in combination. Among these methods, DNA vaccination offers many potential advantages-most notably, ease and low-cost production.…”

Section: Discussionmentioning

confidence: 99%

All-in-One Bacmids: an Efficient Reverse Genetics Strategy for Influenza A Virus Vaccines

Chen

Angel

et al. 2014

J Virol

View full text Add to dashboard Cite

Vaccination is the first line of defense against influenza virus infection, yet influenza vaccine production methods are slow, antiquated, and expensive as a means to effectively reduce the virus burden during epidemic or pandemic periods. There is a great need for alternative influenza vaccines and vaccination methods with a global scale of impact. We demonstrate here a strategy to generate influenza A virus in vivo by using bacmid DNAs. Compared to the classical reverse genetics system, the "eight-in-one" bacmids (bcmd-RGFlu) showed higher efficiency of virus rescue in various cell types. Using a transfection-based inoculation (TBI) system, intranasal delivery to DBA/2J and BALB/c mice of bcmd-RGFlu plus 293T cells led to the generation of lethal PR8 virus in vivo. A prime-boost intranasal vaccination strategy using TBI in the context of a bcmd-RGFlu carrying a temperaturesensitive H1N1 virus resulted in protection of mice against lethal challenge with the PR8 strain. Taken together, these studies provide proof of principle to highlight the potential of vaccination against influenza virus by using in vivo reverse genetics. IMPORTANCEVaccination is the first line of defense against influenza virus infections. A major drawback in the preparation of influenza vaccines is that production relies on a heavily time-consuming process of growing the viruses in eggs. We propose a radical change in the way influenza vaccination is approached, in which a recombinant bacmid, a shuttle vector that can be propagated in both Escherichia coli and insect cells, carries an influenza virus infectious clone (bcmd-RGFlu). Using a surrogate cell system, we found that intranasal delivery of bcmd-RGFlu resulted in generation of influenza virus in mice. Furthermore, mice vaccinated with this system were protected against lethal influenza virus challenge. The study serves as a proof of principle of a potentially universal vaccine platform against influenza virus and other pathogens.

show abstract

Rapid Development of an Efficacious Swine Vaccine for Novel H1N1

Cited by 23 publications

References 20 publications

Viral vector-based influenza vaccines

Viral vector-based influenza vaccines

Swine influenza vaccines: current status and future perspectives

All-in-One Bacmids: an Efficient Reverse Genetics Strategy for Influenza A Virus Vaccines

Contact Info

Product

Resources

About